VRTX Vertex Pharmaceuticals margins

Relative Growth: Rel. Growth:

Relative Strength: Rel. Strength:

Relative Valuation: Rel. Valuation:

Relative Profitability: Rel. Profitability: 93

Gross margin

85.5%

Operating margin

33.2%

EBITDA margin

38.9%

Net margin

30.7%

The Vertex Pharmaceuticals reports a gross margin of 85.5%, an operating margin of 33.2%, an EBITDA margin of 38.9%, and a net margin of 30.7%. Operating margin led the decline across the available margins, contracting by 0.9 percentage points.

VRTX margin history

Gross, operating, EBITDA and net margin trends

Over the last 3 years, Vertex Pharmaceuticals's margins averaged 86.25% gross, 23.01% operating, 29.67% EBITDA, and 20.88% net. For Vertex Pharmaceuticals, operating, EBITDA, and net margins are above their three-year averages, while gross margin is below its three-year average.

VRTX margin expansion

Year-over-year margin changes in percentage points

All available margins contracted year over year, led by operating margin with a decline of 0.9 percentage points.

Gross margin expansion

-0.8pp

Operating margin expansion

-0.9pp

EBITDA margin expansion

-0.8pp

Net margin expansion

-0.6pp

VRTX Gross margin

Over the last 3 years, Vertex Pharmaceuticals's gross margin averaged 86.25%. Currently, Vertex Pharmaceuticals's current gross margin is 85.5%, which is 0.8 percentage points below its three-year average. During this period, gross margin reached a high of 87.2% in Dec 2023 and a low of 85.5% in Sep 2026.

VRTX Operating margin

Over the last 3 years, the average operating margin for Vertex Pharmaceuticals was 23.01%. The current operating margin stands at 33.2%, 10.2 percentage points above its three-year average. Vertex Pharmaceuticals's operating margin ranged from a low of -6.7% in Mar 2025 to a high of 40.7% in Mar 2024.

VRTX EBITDA margin

In the last 3 years, Vertex Pharmaceuticals had an average EBITDA margin of 29.67%. At present, Vertex Pharmaceuticals's current EBITDA margin is 38.9%, which is 9.2 percentage points above its three-year average. Looking back over the last 3 years, Vertex Pharmaceuticals's EBITDA margin reached 49.2% at its highest point in Mar 2024 and -0.7% at its lowest in Mar 2025.

VRTX Net margin

Vertex Pharmaceuticals recorded an average net margin of 20.88% across the last 3 years. The current net margin of 30.7% is 9.8 percentage points above its three-year average. Vertex Pharmaceuticals's net margin ranged from a low of -8.9% in Mar 2025 to a high of 39.5% in Mar 2024.

VRTX margin group comparison

Margins compared with peer-group, industry and sector averages

Vertex Pharmaceuticals's gross margin of 85.5% is higher than the Healthcare sector and its peers average but lower than the industry average. In comparison with the Healthcare sector average of 68.3%, Vertex Pharmaceuticals's gross margin is 25% higher.

VRTX margin peer comparison

Compare margins with selected peers

Frequently asked questions

What is Vertex Pharmaceuticals's gross margin?

The current gross margin for VRTX is 85.5% as of Sep 30, 2026.

What is Vertex Pharmaceuticals's operating margin?

For the period ending Sep 30, 2026, VRTX recorded an operating margin of 33.2%.

What is Vertex Pharmaceuticals's EBITDA margin?

The current EBITDA margin for VRTX is 38.9% as of Sep 30, 2026.

What is Vertex Pharmaceuticals's net margin?

For the period ending Sep 30, 2026, VRTX recorded a net margin of 30.7%.

What are the average margins of VRTX?

The three-year average margins for VRTX were 86.3% gross, 23.0% operating, 29.7% EBITDA, and 20.9% net.

What are the highest historical margins of VRTX?

Over the last 5 years, Vertex Pharmaceuticals's highest margins were 88.1% gross in Jun 2022, 48.2% operating in Jun 2022, 49.7% EBITDA in Dec 2022, and 39.5% net in Mar 2024.

What are the lowest historical margins of VRTX?

Within the 5-year period, VRTX recorded its lowest margins at 85.5% gross in Sep 2026, -6.7% operating in Mar 2025, -0.7% EBITDA in Mar 2025, and -8.9% net in Mar 2025.